Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Mar 2, 2007

CalbaTech Stretches its Stem Cell Microbank Service into the U.K.

  • CalbaTech is creating a subsidiary to enable it to take its stem cell service, the Stem Cell Microbank™, to the U.K. The subsidiary will seek to be listed on the London Stock Exchange.

    CalbaTech focuses on the collection and banking of adult stem cells and providing products and platforms to the biotech, pharma, and academic research markets. It expects that this subsidiary will be managed entirely within the U.K. without distracting from its U.S. focus.

    The company will license to its subsidiary any and all intellectual property related to stem cells along with any new intellectual property that it develops. The reach will be limited to the U.K. with an option for the continent of Europe based on performance.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »